flumatinib
Showing 1 - 8 of 8
Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)
Recruiting
- Chronic Myeloid Leukemia in Chronic Phase
- Flumatinib
- Dasatinib
-
Shenzhen, Guangdong, ChinaShenzhen Second People's Hospital
Jul 26, 2022
Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)
Recruiting
- Flumatinib
- +2 more
- Flumatinib
-
Shenzhen, Guangdong, ChinaThe Second People's Hospital of Shenzhen
Mar 15, 2022
CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)
Not yet recruiting
- CML, Chronic Phase
- Flumatinib
- Imatinib
-
Harbin, Heilongjiang, ChinaInstitute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022
Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,
Recruiting
- Philadelphia Chromosome
- +4 more
- Azacitidine
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jun 23, 2022
Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression Trial in Nanjing (Flumatinib)
Recruiting
- Acute Lymphocytic Leukemia, Adult B-Cell
- BCR-ABL1 Fusion Protein Expression
- Flumatinib
-
Nanjing, Jiangsu, China
- +1 more
Mar 22, 2022
Acute Leukemia Trial in Tianjin (Flumatinib, Imatinib)
Recruiting
- Acute Leukemia
- Flumatinib
- Imatinib
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Sep 27, 2021
Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid
Recruiting
- CML-CP; Mutation;Suboptimal Response or Failure in TKI
- Flumatinib
- Nilotinib
-
Wuhan, Hubei, ChinaWeiming Li
May 31, 2021
Myelogenous Leukemia, Chronic Trial in China (flumatinib, imatinib)
Unknown status
- Myelogenous Leukemia, Chronic
- flumatinib
- imatinib
-
Beijing, Beijing, China
- +4 more
Apr 9, 2013